Celularity expects H1 2024 biomaterial revenue >$24M, Rebound >$9M; reaffirms $50-56M FY guidance

Celularity Inc

Preliminary net revenue from biomaterial products exceeds $24M for six months ended June 30, 2024, surpassing full-year 2023 sales.
Acquired Rebound allograft matrix from Sequence LifeScience; generated >$9M in net revenue to date, reimbursed via HCPCS Q4296.
Reaffirms FY 2024 combined net sales guidance of $50-56M for biomaterial and biobanking businesses.
Plans to file Q2 2024 10-Q in coming weeks; working to regain Nasdaq listing compliance.
Product pipeline: Celularity Tendon Wrap 510(k) submission expected early 2025, FUSE Bone Void Filler H2 2025, Placental Matrix 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.